RNRitambhra Nada

Ritambhra Nada

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ritambhra Nada has a total of 660 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Cytomorphologic Correlates of PD ‐ L1 Expression in Advanced Gallbladder Carcinoma: A Prospective Cross‐Sectional Study Using Fine Needle Aspiration Cell‐Blocks

    by Pragya Verma, Parikshaa Gupta, Pankaj Gupta, Nalini Gupta, Radhika Srinivasan, Ritambhra Nada, Anupam Lal, Usha Dutta

    Background: Programmed death‐ligand 1 (PD‐L1) expression has been evaluated in gallbladder carcinoma (GBC), predominantly in histopathologic specimens, while the cytomorphologic correlates in advanced GBC remain poorly characterized. We evaluated PD‐L1 expression and its cytomorphologic associations in a prospective cohort of advanced GBC diagnosed by fine‐needle aspiration cytology (FNAC). Methods: This prospective study included 70 treatment‐naïve patients with advanced GBC diagnosed by ultrasound‐guided FNAC. PD‐L1 immunocytochemistry was performed on FNAC‐derived cell blocks using the SP263 clone, and the tumour proportion score (TPS) was calculated. Associations between PD‐L1 expression and clinicoradiologic and cytomorphologic parameters were evaluated. Results: PD‐L1 expression (TPS ≥ 1%) was identified in 14/70 (20%) tumours; 10 had TPS 1%–49% and four had TPS ≥ 50%. PD‐L1 expression differed significantly by cytologic subtype ( p = 0.046) and was more frequent in squamous cell carcinoma (4/6; 66.7%) than in conventional adenocarcinoma (9/55; 16.4%) (OR: 10.22; 95% CI: 1.62–64.47). A strong association was observed with nuclear pleomorphism ( p = 0.0001): 8/11 (72.7%) tumours with marked pleomorphism were PD‐L1‐positive compared with 6/56 (10.7%) with moderate pleomorphism (OR: 22.22; 95% CI: 4.60–107.25; Fisher's exact p = 0.0001). PD‐L1 expression was not significantly associated with cytologic grade or clinicoradiologic parameters. Conclusions: PD‐L1 expression was identified in 20% of advanced GBCs diagnosed by FNAC. Marked nuclear pleomorphism and squamous differentiation were strongly associated with PD‐L1 positivity. These findings, although they require further large‐scale validation, expand the cytomorphologic characterization of PD‐L1‐expressing advanced GBC where surgical tissue is unavailable.

  • Open Access

    Neopterin as a Biomarker of Cellular Immune Response in Renal Allograft Rejection Subtypes: Linking Cytokines and Immune Cells to Improve Diagnostic and Therapeutic Approaches

    by Ravi Dhital, Mukut Minz, Ranjana Walker Minz, Shashi Anand, Ritambhra Nada, Sarbpreet Singh, Deepesh B. Kenwar, Ashish Sharma

    Background: Renal allograft rejection remains a major challenge in transplantation. Current diagnostic approaches, including biopsies, are invasive and may fail to detect subclinical immune activation, potentially contributing to progressive graft dysfunction. Reliable, non-invasive biomarkers capable of monitoring immune activation and distinguishing rejection phenotypes are therefore needed. Methods: In this retrospective study, we evaluated serum neopterin as a biomarker of immune activation and graft status over 12 months following transplantation. Associations between neopterin levels and immune parameters, including natural killer (NK)-to-CD3+CD16/CD56+ T cell ratios, cytokines (IFN-γ and IL-10), and CD4+CD25+FoxP3+ T cell frequencies, were assessed. A total of 211 first renal allograft recipients were followed longitudinally, including patients with acute rejection (AR) and matched stable graft (SG) recipients. Serum neopterin was quantified by enzyme immunoassay, and immunophenotyping, mRNA expression, and cytokine profiling were performed on peripheral blood samples. Results: Serum neopterin levels were significantly elevated in AR compared to SG recipients, with a threshold of 57 nmol/L distinguishing AR with 81% sensitivity and 80% specificity. While IFN-γ demonstrated higher diagnostic performance in cross-sectional analysis, neopterin showed a more sustained elevation over time, remaining increased in AR recipients even at later post-transplant time points. Neopterin correlated positively with IFN-γ, but not IL-10, and inversely with CD4+CD25+FoxP3+ T cell frequency. NK cells were enriched during rejection, whereas CD3+CD16/CD56+ T cells were more prominent in graft stability. The NK-to-CD3+CD16/CD56+ T cell ratio was highest during acute cellular rejection. Conclusions: Neopterin reflects Th1-associated immune activation in renal allograft recipients and provides a temporally stable, non-invasive marker of immune status. Although it does not outperform IFN-γ levels at the time of rejection, its stability and sustained elevation suggest a complementary role in longitudinal monitoring. Integration of neopterin with immune parameters, including cytokine profiles and cellular subsets, may enhance the assessment of graft immunological status and support clinical decision-making.

  • Radiological signature of HER2-Positive gallbladder cancer: analysis of CT features

    by Pankaj Gupta, Niharika Dutta, Shravya Singh, Nikita Pradhan, Ruby Siddiqui, Ajay Gulati, Naveen Kalra, Gaurav Prakash, Thakur Yadav, Lileswar Kaman, et al.

    Objective This study aimed to identify distinctive computed tomography (CT) features associated with human epidermal growth factor receptor 2 (HER2) status in gallbladder cancer (GBC) that could serve as noninvasive imaging biomarkers. Materials and methods This study included 213 patients with pathologically confirmed GBCs with availability of HER2 status (171 HER2-negative, 42 HER2-positive). Pre-treatment contrast-enhanced CT scans were evaluated by two radiologists blinded to HER2 status. Multivariate analysis was performed using logistic regression with L2 regularization. Model discrimination was assessed using receiver operating characteristic (ROC) analysis, and internal validation was performed using bootstrap resampling (1,000 iterations) to correct for optimism. Results HER2-positive tumors exhibited larger lymph nodes (1.93 ± 0.79 cm vs. 1.61 ± 0.61 cm, p = 0.015), less frequent gallstones (14.3% vs. 35.7%, p = 0.013), arterial phase hyperenhancement (20.0% vs. 44.1%, p = 0.026), mass-like morphology (35.7% vs. 55.6%, p = 0.033), and more frequent biliary compression by lymph nodes (19.0% vs. 4.1%, p = 0.002). Multivariate analysis identified biliary compression by lymph nodes as the strongest positive predictor of HER2 positivity [odds ratio (OR) 2.99, 95% CI: 1.25–7.04], while arterial phase hyperenhancement (OR 0.40, 95% CI: 0.19–0.75), gallstone presence (OR 0.40, 95% CI: 0.18–0.75), and mass-like morphology (OR 0.54, 95% CI: 0.29–0.95) were significant negative predictors. The model demonstrated good discrimination (area under the ROC curve 0.782) with sensitivity 75%, specificity 79.4%, and negative predictive value 96.2%. Conclusion HER2-positive GBCs display characteristic CT findings that can be utilized for noninvasive diagnosis with robust predictive performance.


  • Open Access

    Clinical Characteristics and Outcomes of Neural Epidermal Growth Factor-like 1 Protein-Associated Membranous Nephropathy

    by Suruthy Narayanasami, Niranjan Anitha Vijayakumar, Mayuri Trivedi, Aravind Sekar, Shabna Sulaiman, Saurabh Nayak, Neeraj Inamdar, Sourabh Sharma, Rajeevalochana Parthasarathy, Vidya Kadam, et al.


  • Open Access

    Cholangiocarcinoma: Recent Advances in Molecular Pathobiology and Therapeutic Approaches

    by Divya Khosla, Shagun Misra, Pek Lim Chu, Peiyong Guan, Ritambhra Nada, Rajesh Gupta, Khwanta Kaewnarin, Tun Kiat Ko, Hong Lee Heng, Vijay Kumar Srinivasalu, et al.

    Cholangiocarcinomas (CCA) pose a complex challenge in oncology due to diverse etiologies, necessitating tailored therapeutic approaches. This review discusses the risk factors, molecular pathology, and current therapeutic options for CCA and explores the emerging strategies encompassing targeted therapies, immunotherapy, novel compounds from natural sources, and modulation of gut microbiota. CCA are driven by an intricate landscape of genetic mutations, epigenetic dysregulation, and post-transcriptional modification, which differs based on geography (e.g., for liver fluke versus non-liver fluke-driven CCA) and exposure to environmental carcinogens (e.g., exposure to aristolochic acid). Liquid biopsy, including circulating cell-free DNA, is a potential diagnostic tool for CCA, which warrants further investigations. Currently, surgical resection is the primary curative treatment for CCA despite the technical challenges. Adjuvant chemotherapy, including cisplatin and gemcitabine, is standard for advanced, unresectable, or recurrent CCA. Second-line therapy options, such as FOLFOX (oxaliplatin and 5-FU), and the significance of radiation therapy in adjuvant, neoadjuvant, and palliative settings are also discussed. This review underscores the need for personalized therapies and demonstrates the shift towards precision medicine in CCA treatment. The development of targeted therapies, including FDA-approved drugs inhibiting FGFR2 gene fusions and IDH1 mutations, is of major research focus. Investigations into immune checkpoint inhibitors have also revealed potential clinical benefits, although improvements in survival remain elusive, especially across patient demographics. Novel compounds from natural sources exhibit anti-CCA activity, while microbiota dysbiosis emerges as a potential contributor to CCA progression, necessitating further exploration of their direct impact and mechanisms through in-depth research and clinical studies. In the future, extensive translational research efforts are imperative to bridge existing gaps and optimize therapeutic strategies to improve therapeutic outcomes for this complex malignancy.


  • Open Access

    Misdiagnosis of carcinoma gall bladder in endemic regions

    by Kunal Bikram Deo, Mohanasundaram Avudaiappan, Sunil Shenvi, Naveen Kalra, Ritambra Nada, Surinder Singh Rana, Rajesh Gupta

    Background: Incidental carcinoma gall bladder and benign disease in radical cholecystectomy specimen is the cause of concern. We attempted to find out the incidence and reasons thereof in the present study. Methods: Present study is a retrospective analysis of a prospectively maintained database between July 2002 and July 2019. All patients with a diagnosis of carcinoma gall bladder admitted for surgery were included. Results: Out of 148 patients, 110 patients had carcinoma gall bladder (CAGB), while 38 patients (25.7%) had incidental carcinoma (under-diagnosis). Radical resection was done in 61/110 (55.4%) patients with clinical CAGB, where 15 (24.6%) patients had benign pathology (“over-diagnosis”). Overdiagnosis was due to xanthogranulomatous cholecystitis (n = 9), chronic cholecystitis (n = 2), tuberculosis (n = 2) and IgG4 related cholecystitis (n = 2). Among 61 patients, a history of weight loss and anorexia were significantly associated with malignancy. Asymmetrical wall thickness was significantly more common in benign mimickers. Among patients with incidental carcinoma, preoperative ultrasonography reported normal wall thickness of gall bladder in 28 (73.7%), thickened gall bladder wall in 6, and polyp in 3 patients. The resectability rate among incidental carcinoma was 27/38 (71.05%). Conclusion: Over-diagnosis of the carcinoma gall bladder was present in 24.6%. On the other hand, incidental carcinoma comprised 25.7% of all admissions for carcinoma gall bladder with resectability of 71%.


  • Open Access

    Giant cephalic venous aneurysm

    by Kishore Abuji, Deepak Kumar, Venkata Vineeth Vaddavalli, Naveen Maheshwari, Ritambhra Nada, Lileswar Kaman, Ajay Savlania


  • Managing ANCA-associated vasculitis during COVID-19 pandemic: a single-center cross-sectional study

    by Joydeep Samanta, Gsrsnk Naidu, Prateek Deo, Sakshi Mittal, Chandra Bhushan Prasad, Diganta Das, Varun Dhir, Shefali Khanna Sharma, Raja Ramachandran, Manish Rathi, et al.

    The objective of the study is to report the outcomes of COVID-19 in ANCA-associated vasculitis (AAV) patients. This was a registry-based observational study conducted at a tertiary care center in north India. AAV patients with at least one follow-up visit between March 2020 and September 2021 were included. Demographic features, clinical manifestations, disease activity, and treatment details of underlying AAV were noted in all patients. Details of COVID-19 infection including severity, treatment, and outcomes were noted. Predictors of COVID-19 severity were determined using univariate analysis. A total of 33 (18.3%) out of 180 AAV patients contracted COVID-19 infection. Moderate COVID-19 infection was seen in 33.3% and severe or critical infection was seen in 36.3% of patients. Seventeen patients (51.5%) required supplemental oxygen therapy. Nine patients had active disease at the time of COVID-19 infection and three of them died due to COVID-19 infection. The risk of COVID-19 infection and its severity did not differ between patients receiving different immunosuppressants including rituximab induction. Hypothyroidism (p = 0.046) and ocular (p = 0.038) involvement due to AAV predicted the development of moderate to severe/critical COVID-19. Three (9.1%) patients died from COVID-19 and the rate of AAV flare after COVID-19 was similar to that in non-COVID-19 patients (15.3/100 person-year vs. 15.6/100 person-year, p = 0.95). Majority of the patients with AAV had moderate to severe or critical COVID-19 infection. The rate of death due to COVID-19 in AAV is higher than in general population. Use of standard remission induction regimens did not lead to increased risk of COVID-19 infection in our AAV cohort.


  • Open Access

    Mesenchymal Stromal Cells Mediate Clinically Unpromising but Favourable Immune Responses in Kidney Transplant Patients

    by Urvashi Kaundal, Raja Ramachandran, Amit Arora, Deepesh B. Kenwar, Ratti Ram Sharma, Ritambhra Nada, Mukut Minz, Vivekanand Jha, Aruna Rakha

    Background. Allograft rejection postkidney transplantation (KTx) is a major clinical challenge despite increased access to a healthcare system and improvement in immunosuppressive (IS) drugs. In recent years, mesenchymal stromal cells (MSCs) have aroused considerable interest in field of transplantation due to their immunomodulatory and regenerative properties. This study was aimed at investigating safety, feasibility, and immunological effects of autologous MSCs (auto-MSCs) and allogeneic MSCs (allo-MSCs) as a complement to IS drug therapy in KTx patients. Methods. 10 patients undergoing KTx with a living-related donor were analysed along with 5 patients in the control group. Patients were given auto-MSCs or allo-MSCs at two time points, i.e., one day before transplant (D-0) and 30 days after transplant (D-30) at the rate of 1.0- MSCs per kg body weight in addition to immunosuppressants. Patients were followed up for 2 years, and 29 immunologically relevant lymphocyte subsets and 8 cytokines and important biomarkers were analysed at all time points. Results. Patients displayed no signs of discomfort or dose-related toxicities in response to MSC infusion. Flow cytometric analysis revealed an increase in B regulatory lymphocyte populations and nonconventional T regulatory cells and a decrease in T effector lymphocyte proportions in auto-MSC-infused patients. No such favourable immune responses were observed in all MSC-infused patients. Conclusion. This study provides evidence that auto-MSCs are safe and well tolerated. This is the first ever report to compare autologous and allogeneic MSC infusion in KTx patients. Importantly, our data demonstrated that MSC-induced immune responses in patients did not completely correlate with clinical outcomes. Our findings add to the current perspective of using MSCs in KTx and explore possibilities through which donor/recipient chimerism can be achieved to induce immune tolerance in KTx patients.


  • ANCA-associated vasculitis following ChAdOx1 nCoV19 vaccination: case-based review

    by Arun Prabhahar, G. S. R. S. N. K. Naidu, Prabhat Chauhan, Aravind Sekar, Aman Sharma, Alok Sharma, Asheesh Kumar, Ritambhra Nada, Manish Rathi, Harbir Singh Kohli, et al.

    For the foreseeable future, vaccines are the cornerstone in the global campaign against the Coronavirus Disease-19 (COVID-19) pandemic. As the number and fatalities due to COVID-19 decline and the lockdown anywise rescinded, we recognize an increase in the incidence of autoimmune disease post-COVID-19 vaccination. However, the causality of the most vaccine-induced side effects is debatable and, at best, limited to a temporal correlation. We herein report a case of a 51-year-old gentleman who developed Anti-Neutrophil Cytoplasmic Antibody (ANCA)-associated vasculitis (AAV) 2 week post-COVID-19 vaccination. The patient responded favorably to oral steroids and rituximab. Additionally, we conducted a case-based review of vaccine-associated AAV describing their clinical manifestations and treatment response of this emerging entity.